Aprutumab, {a specific ADC, offers {a important step forward in treating cancers fueled by FGFR2 mutations. This targeted treatment works by selectively targeting FGFR2, a tyrosine kinase often present in aggressive https://www.targetmol.com/compound/aprutumab